West Pharmaceutical Services Inc (WST)
ÜberbewertetFundamental
66
Kurs
$367.20
Marktkapitalisierung
$26.44B
Teil 1 · Was das Unternehmen wert ist
Übersicht
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$3.33B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$565M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$469M
Gesamtes Eigenkapital
$3.18B
Gesamtverbindlichkeiten
$1.09B
Current Ratio
2.82
Zinsdeckungsgrad
151.20
Schulden/EBITDA
0.42
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$258.38
Aktueller Kurs
$367.20
Sicherheitsmarge
-42.1%
Innerer-Wert-Spanne
$167.95 - $348.82
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
47.47
ROE
15.5%
P/B-Verhältnis
8.73
P/FCF
59.72
Bruttomarge
36.8%
ROIC
15.6%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
15.6%
WACC
10.7%
ROIC − WACC
+4.9 pp
Der ROIC übersteigt die Kapitalkosten: Das Unternehmen schafft Wert für die Aktionäre.
Fundamentalanalyse-Kriterien
Bestanden (21)
- EPS shows upward trend
- EPS CAGR 6.05%
- Price CAGR 15.10%
- ROIC 15.6%
- Gross Margin 36.8%
- Debt/Equity ratio
- Operating Margin 20.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 18.5%
- Revenue Growth 5Y 7.4%
- Analyst Consensus 91% Buy
- Earnings Surprise avg 16.0%
- Earnings Quality (OCF/NI) 1.17
- Share Dilution -1.3%
- Net Margin Trend 17.0% vs 16.5%
- Piotroski F-Score 7/9
Nicht bestanden (6)
- P/FCF 59.72
- P/B Ratio 8.73
- CapEx intensity
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 5.59
Nicht verfügbar (1)
- Dividend Payout NaN%
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Robert W. McMahon C.M.A. | Senior VP & CFO | 56 |
| Ms. Annette F. Favorite | Chief HR Officer & Senior VP | 60 |
| Mr. Shane A. Campbell | SVP & Chief Proprietary Segment Officer | 45 |
| Mr. Michel Lagarde | President, CEO & Director | 50 |
| Mr. Chad R. Winters | VP of Finance & Chief Accounting Officer | 46 |
| Dr. Devesh Mathur | Senior VP & CTO | - |
| Mr. John P. Sweeney C.F.A. | Vice President of Investor Relations | - |
| Mr. Norman D. Finch Jr. | Senior VP, General Counsel & Corporate Secretary | 60 |
| Ms. Michele Polinsky | Vice President of Global Communications | - |
| Mr. Rudy J. Poussot | Senior Vice President of Strategy & Corporate Development | 55 |
Prüfungsrisiko
10
Vorstandsrisiko
9
Vergütungsrisiko
5
Aktionärsrechterisiko
4
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-17
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-07-23
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-07-23
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for WST, sourced from Markets Gazette.
- 4/23/2026POSITIVEWest Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
West Pharmaceutical Services Inc. reported Q1 results that surpassed analyst expectations, driven by robust demand for GLP-1 drug delivery components. The company has consequently raised its full-year 2026 financial guidance, signaling strong confidence in continued growth. Furthermore, West Pharmaceutical announced a new $1 billion share repurchase program, indicating a commitment to returning capital to shareholders. This combination of exceeding current performance, improving future outlook, and enhancing shareholder value makes the stock an attractive prospect for investors.
via Markets Gazette